Clinical Trials
125 trialsEnfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
Memorial Sloan Kettering Cancer Center
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
University of California, Irvine
TRAIN-UC-01
Sun Yat-sen University
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
ARID1A and/or KDM6A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
Pembrolizumab in Muscle-invasive Bladder Cancer
Hoosier Cancer Research Network
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Memorial Sloan Kettering Cancer Center
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SHIELD
China Medical University, China
Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer
IRCCS San Raffaele
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
AVESEC
Gruppo Oncologico Italiano di Ricerca Clinica
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
M.D. Anderson Cancer Center
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
Emory University
IMPROEV
Fox Chase Cancer Center
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
M.D. Anderson Cancer Center
Circulating Tumor DNA Response In Urothelial Cancer
University of Oklahoma
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
Massachusetts General Hospital
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
SOGUG-NEOWIN
Spanish Oncology Genito-Urinary Group
Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium
M.D. Anderson Cancer Center
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
TALASUR
Centre Francois Baclesse
Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
University of Florida
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
GRAPE
Nagoya University
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
NEPTUNE
University of Michigan Rogel Cancer Center
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
University of Southern California
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Thomas Jefferson University
AUREA
Spanish Oncology Genito-Urinary Group
PEGASUS
European Association of Urology Research Foundation
ACROPOLI
SOLTI Breast Cancer Research Group
ABACUS
Queen Mary University of London
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Case Comprehensive Cancer Center
ABLE
University of Michigan Rogel Cancer Center
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
Hoosier Cancer Research Network
PemCab
University of Utah
Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma
University of Washington
Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
University of Florida
ICONIC
CNAO National Center of Oncological Hadrontherapy
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University